VALUE-DX

VALUE-Dx is the first Innovative Medicines Initiative project initiated by 6 in vitro diagnostic companies who joined forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. Unique in its multidisciplinary consortium, it involves clinicians, microbiologists, health economists, social scientists, and industry, to help build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance... Our vision is to transform clinical practice, improve patient outcomes, and combat AMR, through the widespread use of clinical and cost-effective innovative diagnostics strategies to achieve more personalised, evidence-based antibiotic prescription and use in community care settings... Our purpose is to facilitate and accelerate the rigorous assessment and implementation of (new) diagnostic technologies into healthcare settings, by establishing the infrastructure, methods, processes and approaches..